Insight into Binding of Phosphodiesterase-9A Selective Inhibitors by Crystal Structures and Mutagenesis

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1726-1731

  Wang, Huanchen ^a   Luo, Xuan ^a,b   Ye, Mengchun ^a   Hou, Jing ^b   Robinson, Howard ^c   Ke, Hengming ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROPHENYL) 6 (3,3,3 TRIFLUORO 2 METHYLPROPYL) 1H PYRAZOLO[3,4 D]PYRIMIDINE 4(5H) ONE; BAY 73 6691; PHOSPHODIESTERASE 9A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENANTIOMER; MUTAGENESIS; NUCLEOTIDE SEQUENCE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PYRAZOLES; PYRIMIDINES; STEREOISOMERISM;

EID: 77649229897     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901519f     Document Type: Article

References (40)

1. Houslay, M. D. Adaptation in cyclic AMP signaling processes: a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev. Biol. 1998, 9, 161-167.
2. Antoni, F. Molecular diversity of cyclic AMP signaling. Front. Neuroendocrinol. 2000, 21, 103-132. (Pubitemid 30228501)
3. Zaccolo, M.; Movsesian, M. A. cAMP and cGMP signaling crosstalk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 2007, 100, 1569-1578. (Pubitemid 46897260)
4. Piper, M.; van Horck, F.; Holt, C. The role of cyclic nucleotides in axon guidance. Adv. EXP. Med. Biol. 2007, 621, 134-143.
5. O'Neill, J. S.; Maywood, E. S.; Chesham, J. E.; Takahashi, J. S.; Hastings, M. H. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science 2008, 320, 949-953. (Pubitemid 351929593)
6. Horvath, A.; Stratakis, C. A. Unraveling the molecular basis of micronodular adrenal hyperplasia. Curr. Opin. Endocrinol., Diabetes Obes. 2008, 15, 227-233.
7. Hannila, S. S.; Filbin, M. T. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord, injury. EXP. Neurol. 2008, 209, 321-332. (Pubitemid 351174133)
8. Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
9. Omori, K.; Kotera, J. Overview of PDEs and their regulation. Circ. Res. 2007, 100, 309-327.
10. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu, Rev. Biochem. 2007, 76, 481-511.
11. Soderhng, S. H.; Bayuga, S. J.; Beavo, J. A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 1998, 273, 15553-15558.
12. Fisher, D. A.; Smith, J. F.; Pillar, J. S.; St. Denis, S. H.; Cheng, J. B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. J. Biol. Chem. 1998, 273, 15559-15564.
13. Wang, P.; Wu, P.; Egan, R. W.; Billah, M. M. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5) differential tissue distribution, and subcellular localization of PDE9A variants. Gene 2003, 314, 15-27.
14. Huai, Q.;Wang, H.; Zhang, W.; Colman, R. W.; Robinson, H.; Ke, H. Crystal structure of phosphodiesterase 9 shows orientation variation, of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl, Acad. Sci. U.S.A. 2004, 101, 9624-9629.
15. McCarty, M. F. cGMP may have trophic effects on beta cell function comparable to those of cAMP, implying a role for highdose biotin in prevention/treatment of diabetes. Med. Hypotheses 2006, 66, 323-328.
16. Van. Staveren, W. C.; Steinbusch, H. W.; Markerink-Van Ittersum, M.; Repaske, D. R.; Goy, M. F.; Kotera, J.; Omori, K.; Beavo, J. A.; De Vente, J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol. 2003, 467, 566-580.
17. de Vente, J.; Markerink-van Ittersum, M.; Vles, J. S. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord. J. Chem, Neuroanat. 2006, 31, 275-303.
18. Diederen, R. M.; La Heij, E. C.; Markerink-van Ittersum, M.; Kijlstra, A.; Hendrikse, F.; de Vente, J. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells. Br. J. Ophthalmol. 2007, 91, 379-384.
19. Fryburg, D. A.; et al. Treatment of Insulin Resistance Syndrome and. Type 2 Diabetes with PDE9 Inhibitors. WO 03/037432 A1, 2003.
20. Deninno, M. P.; et al. PDE9 Inhibitors for Treating Cardiovascular Disorders. WO 03/037899, 2003; Pfizer Inc.
21. Bell, A. S.; et al. PDE9 Inhibitors for Treating Type 2 Diabetes, Metabokic Syndrome, and Cardiovasculate Disease. WO 2004/ 096811, 2004.
22. Deninno, M. P.; Andrews, M.; Bell, A. S.; Chen, Y.; Eller-Zarbo, C.; Eshelby, N.; Etienne, J. B.; Moore, D. E.; Palmer, M. J.; Visser, M. S.; Yu, L. J.; Zavadoski, W. J.; Michael Gibbs, E. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg. Med. Chem. Lett. 2009, 19, 2537-2541.
23. Black, S. C.; Gibbs, E. M.; McNeish, J. D. Phosphodiesterase 9 Inhibition as Treatment for Obesity-Related Conditions. WO 2005/041972, 2005.
24. van Staveren, W. C.; Glick, J.; Markerink-van Ittersum, M.; Shimizu, M.; Beavo, J. A.; Steinbusch, H. W.; de Vente, J. Cloning and localization, of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol. 2002, 31, 729-741.
25. Hendrix, M.; et al. 6-Arylamino-5-cyano-4-pynmidinones as PDE9A Inhibitors. WO 2004/113306, 2004.
26. Reyes-Irisarri, E.; Markerink-Van Ittersum, M.; Mengod, G.; de Vente, J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci. 2007, 25,3332-3338.
27. van der Staay, F. J.; Rutten, K.; Bärfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K. G.; Schröder, U. H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008, 55, 908-918.
28. Reneerkens, O. A.; Rutten, K.; Steinbusch, H. W.; Blokland, A.; Prickaerts, J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berlin. Ger:) 2009, 202, 419-443.
29. Liu, S.; Mansour, M. N.; Dillman, K. S.; Perez, J. R.; Danley, D. E.; Aeed, P. A.; Simons, S. P.; Lemotte, P. K.; Menniti, F. S. Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13309-13314.
30. Wunder, F.; Tersteegen, A.; Rebmann, A.; Erb, C.; Fahrig, T.; Hendrix, M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 2005, 68, 1775-1781.
31. Ke, H.; Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr. Top, Med, Chem. 2007, 7, 391-403.
32. Huai, Q.; Colicelli, J.; Ke, H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 2003, 42, 13220-13226.
33. Wang, H.; Liu, Y.; Huai, Q.; Cai, J.; Zoraghi, R.; Francis, S. H.; Corbin, .T. D.; Robinson, H.; Xin, Z.; Lin, G.; Ke, H. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J. Biol. Chem. 2006, 281, 21469-21479.
34. Wang, H.; Robinson, H.; Ke, H. The molecular basis for recognition of different substrates by phosphodiesterase families 4 and 10. J. Mol. Biol. 2007, 371, 302-307.
35. Wang, H.; Ye, M.; Robinson, H.; Francis, S. H.; Ke, H. Conformational variations of both PDE5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol. Pharmacol. 2008, 73, 104-110.
36. Wang, H.; Yan, Z.; Yang, S.; Cai, J.; Robinson, H.; Ke, H. Kinetic and structural studies of phosphodiesterase-SA. and implication on the inhibitor selectivity. Biochemistry 2008, 47,12760-12768.
37. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
38. Navaza, J.; Saludjian, P. AMoRe: an automated molecular replacement program package. Methods Enzymol. 1997, 276, 581-594.
39. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved, methods for building protein, models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47, 110-119.
40. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.;Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.